NUPLAZID: Real help for a real part of Parkinson’s disease.
NUPLAZID® (pimavanserin) is the only medicine FDA-approved to reduce the frequency and/or severity of hallucinations and delusions associated with Parkinson’s disease psychosis.
Did you know that around 50% of people living with Parkinson’s may experience hallucinations or delusions over the course of their disease?
Not actual size
John is affected by hallucinations and delusions associated with Parkinson's disease. In this video, John speaks about the impact these have had on him, and his experience taking NUPLAZID® (pimavanserin) to treat these symptoms.
"I can hopefully help people coming out and talking about this so they don’t fall into the trap and suffer as long as I did."
Individual results may vary.
Facts about NUPLAZID
NUPLAZID WORKS AROUND THE CLOCK TO HELP REDUCE PARKINSON’S DISEASE HALLUCINATIONS AND DELUSIONS.
NUPLAZID works all day and night to help reduce hallucinations and delusions associated with Parkinson’s disease psychosis. You just take one 34 mg capsule, once daily by mouth, with or without food, around the same time every day, or as prescribed by your healthcare provider. It’s important to remember that everyone responds to medications differently, so it may take some time for NUPLAZID to start working.
CONTINUING TO TAKE NUPLAZID AS PRESCRIBED MAY HELP YOU SEE RESULTS.
NUPLAZID may begin to reduce hallucinations and delusions as soon as 4 weeks, but it may take up to 6 weeks to feel the full effect. You should speak with your healthcare provider before you stop taking NUPLAZID.
NUPLAZID REDUCED THE FREQUENCY AND/OR SEVERITY OF PARKINSON'S-RELATED HALLUCINATIONS AND DELUSIONS.
In the clinical trial, the majority of patients who took NUPLAZID experienced fewer and/or less severe hallucinations and delusions. And some patients did not experience any hallucinations or delusions after 6 weeks. Not everyone will respond to NUPLAZID.
To test the efficacy of NUPLAZID, an FDA-accepted tool was used. The tool measures changes in the frequency or severity of hallucinations and delusions in people with Parkinson’s.
The clinical trial included 199 adults (at least 40 years of age with a mean age of 72 years) diagnosed with Parkinson’s disease psychosis that was severe enough for treatment. It was a randomized, double-blind, placebo-controlled study. Each person was assigned to 1 of 2 groups: those who received NUPLAZID 34 mg or those who received placebo. Results were reported after 6 weeks.
TAKING NUPLAZID DOESN’T REQUIRE ADJUSTING DOSES OF CARBIDOPA/LEVODOPA.
You can take NUPLAZID without adjusting doses of carbidopa/levodopa medicines. Some medicines should not be taken with NUPLAZID. Tell your healthcare provider about any changes in the medicines you are taking. Some prescriptions or OTC medicines may interact with NUPLAZID.
NUPLAZID HAS NO EFFECT ON MOTOR SYMPTOMS.
Taking NUPLAZID 34 mg did not affect motor symptoms during a clinical trial, compared to a placebo.
TELL YOUR HEALTHCARE PROVIDER ABOUT ALL THE MEDICINES YOU TAKE.
NUPLAZID may increase the risk of changes to your heart rhythm. This risk may increase if NUPLAZID is taken with certain other medications known to prolong the QT interval. Some medicines should not be taken with NUPLAZID.
Do not take NUPLAZID if you have certain heart conditions that change your heart rhythm. It is important to talk to your healthcare provider about the possible side effect of changes to your heart rhythm. Call your healthcare provider if you feel a change in your heartbeat.